

# Giuseppe Palmieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4478616/publications.pdf>

Version: 2024-02-01

208  
papers

16,389  
citations

81900

39  
h-index

16183

124  
g-index

219  
all docs

219  
docs citations

219  
times ranked

21292  
citing authors

#	ARTICLE	IF	CITATIONS
1	Red Blood Cell Distribution Width (RDW) Correlates to the Anatomical Location of Colorectal Cancer. Implications for Clinical Use. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 259-264.	1.3	4
2	Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 213-221.	2.4	8
3	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 32.	2.0	5
4	Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup. <i>ESMO Open</i> , 2022, 7, 100525.	4.5	10
5	The prognostic impact of the extent of ulceration in patients with clinical stage Iâ€œâ€ melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). <i>British Journal of Dermatology</i> , 2021, 184, 281-288.	1.5	10
6	Whole-exome Sequencing of Prostate Cancer in Sardinian Identify Recurrent UDP-glucuronosyltransferase Amplifications. <i>Journal of Cancer</i> , 2021, 12, 438-450.	2.5	5
7	Molecular Landscape Profile of Melanoma. , 2021, , 31-55.		0
8	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 612.	4.1	79
9	Repurposing Anticancer Drugs for the Treatment of Idiopathic Pulmonary Fibrosis and Antifibrotic Drugs for the Treatment of Cancer: State of the Art. <i>Current Medicinal Chemistry</i> , 2021, 28, 2234-2247.	2.4	7
10	Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 666624.	2.8	5
11	Anticancer Activity of Two Novel Hydroxylated Biphenyl Compounds toward Malignant Melanoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5636.	4.1	10
12	The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7160.	4.1	4
13	Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 728113.	2.8	1
14	KIT and PDGFRA mutational patterns in Sardinian patients with gastrointestinal stromal tumors. <i>European Journal of Cancer Prevention</i> , 2021, 30, 53-58.	1.3	2
15	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , 2021, 11, 672797.	2.8	2
16	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103118.	4.4	17
17	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2430.	2.4	10
18	Primary Melanoma of the Lung: A Systematic Review. <i>Medicina (Lithuania)</i> , 2020, 56, 576.	2.0	12

#	ARTICLE	IF	CITATIONS
19	MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. <i>Melanoma Research</i> , 2020, 30, 500-510.	1.2	6
20	Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI). <i>Diagnostic Pathology</i> , 2020, 15, 143.	2.0	0
21	Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiReÂ® Panel. <i>Frontiers in Oncology</i> , 2020, 10, 236.	2.8	11
22	Genetic Instability Markers in Cancer. <i>Methods in Molecular Biology</i> , 2020, 2055, 133-154.	0.9	2
23	Long Noncoding RNAs in Non-Small Cell Lung Cancer: State of the Art. <i>RNA Technologies</i> , 2020, , 305-325.	0.3	0
24	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	2.6	24
25	New paradigm for stage III melanoma: from surgery to adjuvant treatment. <i>Journal of Translational Medicine</i> , 2019, 17, 266.	4.4	27
26	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 756-767.	2.8	37
27	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 209.	2.0	29
28	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
29	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	4.4	24
30	Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways. <i>Metallomics</i> , 2019, 11, 1687-1699.	2.4	41
31	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. <i>Journal of Clinical Medicine</i> , 2019, 8, 1577.	2.4	9
32	Dietary compounds and cutaneous malignant melanoma: recent advances from a biological perspective. <i>Nutrition and Metabolism</i> , 2019, 16, 33.	3.0	13
33	Circulating driver gene mutations: what is the impact on melanoma patientsâ€™ management?. <i>Annals of Oncology</i> , 2019, 30, 669-671.	1.2	3
34	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 332-342.	5.6	16
35	Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases. <i>Diagnostics</i> , 2019, 9, 42.	2.6	0
36	Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature. <i>Clinical Respiratory Journal</i> , 2018, 12, 848-856.	1.6	6

#	ARTICLE	IF	CITATIONS
37	The DISTINCTIVE study: A biologically enriched phase II study of second-line folfox4/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status - Trial in progress. <i>Annals of Oncology</i> , 2018, 29, v82.	1.2	3
38	Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. <i>Current Oncology Reports</i> , 2018, 20, 86.	4.0	61
39	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 69, 21-28.	7.7	31
40	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. <i>International Journal of Oncology</i> , 2018, 53, 1149-1159.	3.3	12
41	Pathology and Genetics of Melanoma. , 2018, , .		0
42	Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations. <i>European Journal of Dermatology</i> , 2018, 28, 149-156.	0.6	5
43	Genetic alterations in main candidate genes during melanoma progression. <i>Oncotarget</i> , 2018, 9, 8531-8541.	1.8	50
44	Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy. <i>European Journal of Cancer Prevention</i> , 2017, 26, 263-267.	1.3	24
45	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 17.	4.4	40
46	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	4.4	85
47	Long non-coding RNA CASC2 in human cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 31-38.	4.4	54
48	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017, 6, e1283462.	4.6	34
49	Antitumoral effect of vanadium compounds in malignant melanoma cell lines. <i>Journal of Inorganic Biochemistry</i> , 2017, 174, 14-24.	3.5	66
50	Vitamin D status and risk for malignant cutaneous melanoma: recent advances. <i>European Journal of Cancer Prevention</i> , 2017, 26, 532-541.	1.3	30
51	Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. <i>International Journal of Dermatology</i> , 2017, 56, 792-794.	1.0	4
52	A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. <i>Hepatology</i> , 2017, 66, 167-181.	7.3	119
53	Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017, 38, 2741-2751.	2.6	22
54	Female Adnexal Tumors of Probable Wolffian Origin (FATWO): A Case Series With Next-Generation Sequencing Mutation Analysis. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 575-581.	1.4	21

#	ARTICLE	IF	CITATIONS
55	Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. <i>Retrovirology</i> , 2017, 14, 3.	2.0	9
56	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. <i>Journal of Translational Medicine</i> , 2017, 15, 227.	4.4	10
57	Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. <i>Oncotarget</i> , 2017, 8, 90638-90650.	1.8	17
58	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. <i>Oncotarget</i> , 2017, 8, 80393-80404.	1.8	16
59	What is changing in the adjuvant treatment of melanoma?. <i>Oncotarget</i> , 2017, 8, 110735-110736.	1.8	2
60	Perivascular Epithelioid Cell Tumors (PEComas) of the Orbit. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 7-8.	1.1	5
61	Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6. <i>BMC Cancer</i> , 2016, 16, 317.	2.6	8
62	Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. <i>Oncogenesis</i> , 2016, 5, e274-e274.	4.9	28
63	Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma. <i>Oncology Letters</i> , 2016, 12, 1415-1421.	1.8	3
64	Breast Nodular Fasciitis: A Comprehensive Review. <i>Breast Care</i> , 2016, 11, 270-274.	1.4	32
65	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.	0.7	13
66	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. <i>Journal of Translational Medicine</i> , 2016, 14, 292.	4.4	43
67	Association of Melanocortin-1 Receptor Variants with Pigmentary Traits in Humans: A Pooled Analysis from the M-Skip Project. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1914-1917.	0.7	16
68	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.	1.2	32
69	Antitumor Activity of BRAF Inhibitor and IFN $\gamma$ Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv435.	6.3	35
70	<i>MC1R</i> variants increased the risk of sporadic cutaneous melanoma in darker pigmented Caucasians: A pooled analysis from the M-Skip project. <i>International Journal of Cancer</i> , 2015, 136, 618-631.	5.1	92
71	Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1033-1034.	3.7	1
72	Epidemiological features and prognostic parameters of multiple primary melanomas in CDKN2A-mutations patients. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 747-751.	3.3	2

#	ARTICLE	IF	CITATIONS
73	Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Management</i> , 2015, 2, 149-163.	0.5	3
74	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. <i>Molecular Medicine Reports</i> , 2015, 12, 187-191.	2.4	14
75	A Study of Inflammatory/Necrosis Biomarkers in the Fracture of the Femur Treated with Proximal Femoral Nail Antirotation. <i>Mediators of Inflammation</i> , 2015, 2015, 1-5.	3.0	9
76	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183.	2.8	80
77	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	4.6	28
78	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. <i>Journal of Translational Medicine</i> , 2015, 13, 37.	4.4	15
79	Genome-wide association study of susceptibility loci for breast cancer in Sardinian population. <i>BMC Cancer</i> , 2015, 15, 383.	2.6	12
80	CDKN2A mutations could influence the dermoscopic pattern of presentation of multiple primary melanoma: a clinical dermoscopic genetic study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 574-580.	2.4	9
81	4-Substituted-2-Methoxyphenol: Suitable Building Block to Prepare New Bioactive Natural-like Hydroxylated Biphenyls. <i>Letters in Drug Design and Discovery</i> , 2014, 12, 131-139.	0.7	6
82	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	4.6	318
83	Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. <i>Oncology Letters</i> , 2014, 7, 948-952.	1.8	16
84	ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy. <i>Journal of Translational Medicine</i> , 2014, 12, 272.	4.4	8
85	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. <i>Metabolomics</i> , 2014, 10, 1026-1035.	3.0	7
86	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 216.	4.4	43
87	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
88	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	4.4	24
89	KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. <i>Oncology Letters</i> , 2014, 8, 1422-1426.	1.8	21
90	Molecular Pathology of Melanocytic Skin Cancer. , 2014, , 59-74.		0

#	ARTICLE	IF	CITATIONS
91	Epidemiology of malignant pleural mesothelioma in the province of Sassari (Sardinia, Italy). A population-based report. <i>Annali Italiani Di Chirurgia</i> , 2014, 85, 244-8.	0.1	3
92	Uterine perivascular epithelioid cell neoplasms (PEComas): report of two cases and literature review. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2014, 35, 309-12.	0.2	9
93	Do BRAF inhibitors select for populations with different disease progression kinetics?. <i>Journal of Translational Medicine</i> , 2013, 11, 61.	4.4	25
94	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- $\gamma$ in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	4.4	21
95	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. <i>BMC Cancer</i> , 2013, 13, 17.	2.6	38
96	Molecular changes induced by the curcumin analogue D6 in human melanoma cells. <i>Molecular Cancer</i> , 2013, 12, 37.	19.2	21
97	Lung cancer epidemiology in North Sardinia, Italy. <i>Multidisciplinary Respiratory Medicine</i> , 2013, 8, 45.	1.5	29
98	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	4.4	31
99	Unexpected Distribution of <i>ckIT</i> and <i>BRAF</i> Mutations among Southern Italian Patients with Sinonasal Melanoma. <i>Dermatology</i> , 2013, 226, 279-284.	2.1	36
100	Epidemiology of Thyroid Cancer in an Area of Epidemic Thyroid Goiter. <i>Journal of Cancer Epidemiology</i> , 2013, 2013, 1-4.	1.1	11
101	Mutations in ERBB4 May Have a Minor Role in Melanoma Pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1685-1687.	0.7	8
102	Primary Dermal Melanoma in a Patient with a History of Multiple Malignancies: A Case Report with Molecular Characterization. <i>Case Reports in Dermatology</i> , 2013, 5, 192-197.	0.8	7
103	Diagnostic Services for Melanoma in Italy. <i>Dermatology</i> , 2013, 226, 3-6.	2.1	2
104	Estimates of cancer burden in Sardinia. <i>Tumori</i> , 2013, 99, 408-15.	1.1	7
105	In vitro activity of the $\alpha_3\beta_1$ integrin antagonist RGDechi-hCit on malignant melanoma cells. <i>Anticancer Research</i> , 2013, 33, 871-9.	1.1	22
106	BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. <i>Cell Death and Disease</i> , 2012, 3, e259-e259.	6.3	74
107	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	1.6	419
108	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0

#	ARTICLE	IF	CITATIONS
109	NF- $\kappa$ B as potential target in the treatment of melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 53.	4.4	118
110	Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. <i>Journal of Translational Medicine</i> , 2012, 10, 178.	4.4	31
111	NF- $\kappa$ B is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. <i>Journal of Translational Medicine</i> , 2012, 10, 252.	4.4	32
112	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	4.4	563
113	Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies. <i>BMC Medical Research Methodology</i> , 2012, 12, 116.	3.1	12
114	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0.8 24	0.8	24
115	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. <i>Familial Cancer</i> , 2012, 11, 41-47.	1.9	32
116	Proteomic Profiling of Human Melanoma Metastatic Cell Line Secretomes. <i>Journal of Proteome Research</i> , 2011, 10, 4703-4714.	3.7	23
117	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. <i>Oncology Reports</i> , 2011, 25, 899-904.	2.6	1
118	Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011, 25, 1495-502.	2.6	19
119	Mutation frequency in <i>BRAF</i> and <i>NRAS</i> genes among primary tumors and different types of metastasis from melanoma patients. <i>Journal of Clinical Oncology</i> , 2011, 29, 8574-8574.	1.6	3
120	Monitoring liver alterations during hepatic tumorigenesis by NMR profiling and pattern recognition. <i>Metabolomics</i> , 2010, 6, 405-416.	3.0	11
121	Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. <i>BMC Cancer</i> , 2010, 10, 458.	2.6	11
122	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. <i>Clinical Immunology</i> , 2010, 134, 237-250.	3.2	131
123	The role of spectrophotometry in the diagnosis of melanoma. <i>BMC Dermatology</i> , 2010, 10, 5.	2.1	13
124	The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. <i>Annals of Oncology</i> , 2010, 21, 1379-1380.	1.2	6
125	Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. <i>Molecular Cancer</i> , 2010, 9, 137.	19.2	44
126	Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon- $\gamma$ 2b treatment. <i>Journal of Translational Medicine</i> , 2010, 8, 76.	4.4	39



#	ARTICLE	IF	CITATIONS
127	Reply to Antisense oligonucleotide targeting Bcl-2 mRNA in cancer; bad drug, bad target, neither or both?. <i>Annals of Oncology</i> , 2009, 20, 597.	1.2	0
128	A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. <i>Cell Cycle</i> , 2009, 8, 1228-1237.	2.6	11
129	A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population. <i>BMC Cancer</i> , 2009, 9, 245.	2.6	18
130	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009, 9, 352.	2.6	42
131	Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. <i>BMC Cancer</i> , 2009, 9, 62.	2.6	16
132	Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. <i>BMC Dermatology</i> , 2009, 9, 7.	2.1	8
133	NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009, 274, 331-336.	7.2	30
134	Main roads to melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 86.	4.4	157
135	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. <i>Melanoma Research</i> , 2009, 19, 142-145.	1.2	20
136	Presence of Jaagsiekte sheep retrovirus in tissue sections from human bronchioloalveolar carcinoma depends on patients' geographical origin. <i>Human Pathology</i> , 2008, 39, 303-304.	2.0	16
137	Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Annals of Oncology</i> , 2008, 19, 2092-2093.	1.2	10
138	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. <i>Journal of Clinical Oncology</i> , 2007, 25, e20-e21.	1.6	13
139	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. <i>European Journal of Cancer</i> , 2007, 43, 137-143.	2.8	28
140	Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells. <i>Molecular Cancer</i> , 2007, 6, 8.	19.2	106
141	2,2-Dihydroxy-3,3-dimethoxy-5,5-dimethyl-6,6-dibromo-1,1-biphenyl: preparation, resolution, structure and biological activity. <i>Tetrahedron: Asymmetry</i> , 2007, 18, 414-423.	1.8	4
142	Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. <i>British Journal of Dermatology</i> , 2007, 158, 071119222739015-???	1.5	37
143	Origin and distribution of the BRCA2-8765delAG mutation in breast cancer. <i>BMC Cancer</i> , 2007, 7, 132.	2.6	15
144	Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1052-1068.	3.6	27

#	ARTICLE	IF	CITATIONS
145	CASC2a gene is down-regulated in endometrial cancer. <i>Anticancer Research</i> , 2007, 27, 235-43.	1.1	47
146	Adjuvant treatment of malignant melanoma: Where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 45-52.	4.4	10
147	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. <i>BMC Cancer</i> , 2006, 6, 266.	2.6	19
148	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005, 15, 235-244.	1.2	50
149	Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening. <i>Cancer</i> , 2005, 104, 1172-1179.	4.1	24
150	Identification of predictive factors for the occurrence of predisposing MLH1 and MSH2 germline mutations among Sardinian patients with colorectal carcinoma. <i>European Journal of Cancer</i> , 2005, 41, 1058-1064.	2.8	4
151	Overexpression of h-prune in breast cancer is correlated with advanced disease status. <i>Clinical Cancer Research</i> , 2005, 11, 199-205.	7.0	32
152	Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells. <i>Cancer Research</i> , 2004, 64, 3037-3045.	0.9	233
153	BRAF Gene Is Somaticallly Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 286-292.	1.6	55
154	Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. <i>Cancer Cell</i> , 2004, 5, 137-149.	16.8	132
155	Distribution and significance of 14-3-3 $\sigma$ , a novel myoepithelial marker, in normal, benign, and malignant breast tissue. <i>Journal of Pathology</i> , 2004, 202, 274-285.	4.5	67
156	Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. <i>Human Mutation</i> , 2004, 23, 318-326.	2.5	86
157	High-resolution methylation analysis of the MLH1 promoter in sporadic endometrial and colorectal carcinomas. <i>Cancer</i> , 2003, 98, 1540-1546.	4.1	31
158	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
159	X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3311-3314.	7.1	121
160	Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases. <i>Annals of Oncology</i> , 2003, 14, 1530-1536.	1.2	14
161	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. <i>International Journal of Oncology</i> , 2003, 22, 1209.	3.3	11
162	Mutation analysis of candidate genes in melanoma-prone families. <i>Melanoma Research</i> , 2003, 13, 571-579.	1.2	11

#	ARTICLE	IF	CITATIONS
163	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003, 13, 167-170.	1.2	35
164	Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. <i>International Journal of Oncology</i> , 2003, 22, 1209-15.	3.3	5
165	BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. <i>Annals of Oncology</i> , 2002, 13, 1899-1907.	1.2	20
166	Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1447-1453.	1.2	38
167	Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. <i>European Journal of Cancer</i> , 2002, 38, 1802-1809.	2.8	35
168	Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. <i>Cancer</i> , 2002, 94, 3157-3168.	4.1	39
169	Mutations of the BRAF gene in human cancer. <i>Nature</i> , 2002, 417, 949-954.	27.8	9,374
170	Adjuvant therapy of melanoma: what's new?. <i>Melanoma Research</i> , 2002, 12, 293-296.	1.2	4
171	Detection of tyrosinase mRNA in tumor tissue microdissections from classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2001, 12, 1765-1766.	1.2	0
172	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. <i>Journal of Clinical Oncology</i> , 2001, 19, 1437-1443.	1.6	63
173	Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients. <i>Recent Results in Cancer Research</i> , 2001, 158, 200-203.	1.8	19
174	Mobile hospital rooms to fight melanoma. <i>Melanoma Research</i> , 2001, 11, 83-84.	1.2	1
175	Low doses interferon- $\alpha$ in the treatment of high-risk cutaneous melanoma. <i>Annals of Oncology</i> , 2000, 11, 487-490.	1.2	2
176	Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. <i>Annals of Oncology</i> , 2000, 11, 1504.	1.2	4
177	Intermediate dose recombinant interferon- $\gamma$ as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. <i>Cancer</i> , 2000, 89, 1490-1494.	4.1	9
178	Microsatellite analysis at 10q25-q26 in Sardinian patients with sporadic endometrial carcinoma. <i>Cancer</i> , 2000, 89, 1773-1782.	4.1	11
179	Cisplatin, dacarbazine, and fotemustine plus interferon $\alpha$ in patients with advanced malignant melanoma. <i>Cancer</i> , 2000, 89, 2630-2636.	4.1	21
180	Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. <i>British Journal of Dermatology</i> , 2000, 142, 893-898.	1.5	60

#	ARTICLE	IF	CITATIONS
181	Identification of a founder BRCA2 mutation in Sardinia. <i>British Journal of Cancer</i> , 2000, 82, 553-559.	6.4	42
182	Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. <i>British Journal of Cancer</i> , 2000, 83, 1707-1714.	6.4	40
183	Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2000, 11, 635-636.	1.2	3
184	Human dbl proto-oncogene in 85 kb of Xq26, and determination of the transcription initiation site. <i>Gene</i> , 2000, 253, 107-115.	2.2	3
185	Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. <i>Cancer</i> , 2000, 89, 2630-6.	4.1	4
186	Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. <i>Journal of Clinical Oncology</i> , 1999, 17, 304-304.	1.6	109
187	3-year treatment with recombinant interferon-alpha as adjuvant therapy of cutaneous malignant melanoma. <i>International Journal of Molecular Medicine</i> , 1999, 3, 303-6.	4.0	6
188	Adjuvant therapy of cutaneous melanoma. <i>Lancet</i> , The, 1999, 353, 328.	13.7	8
189	Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. <i>Melanoma Research</i> , 1998, 8, 529-538.	1.2	25
190	Construction of a pilot human YAC library in a recombination-defective yeast strain. <i>Gene</i> , 1997, 188, 169-174.	2.2	6
191	Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. <i>European Journal of Cancer</i> , 1996, 32, 1719-1726.	2.8	10
192	Significance of Methotrexate Serum Level Achieved in Patients with Gastrointestinal Malignancies Treated with Sequential Methotrexate, &Folinic Acid and 5-Fluorouracil. <i>Oncology</i> , 1996, 53, 198-203.	1.9	5
193	A compositional map of human chromosome band Xq28. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 1298-1302.	7.1	39
194	YAC Contig Organization and CpG Island Analysis in Xq28. <i>Genomics</i> , 1994, 24, 149-158.	2.9	44
195	Combination of Vinorelbine, Cisplatin, and Etoposide in Advanced Non-Small Cell Lung Carcinoma: A Pilot Study. <i>Journal of Chemotherapy</i> , 1994, 6, 67-71.	1.5	18
196	Type 2 Vasopressin Receptor Gene, the Gene Responsible for Nephrogenic Diabetes Insipidus, Maps to XQ28 Close to the L1CAM Gene. <i>Biochemical and Biophysical Research Communications</i> , 1993, 193, 864-871.	2.1	13
197	1.5-Mb YAC Contig in Xq28 Formatted with Sequence-Tagged Sites and Including a Region Unstable in the Clones. <i>Genomics</i> , 1993, 16, 586-592.	2.9	14
198	Actin-Binding Protein (ABP-280) Filamin Gene (FLN) Maps Telomeric to the Color Vision Locus (R/GCP) and Centromeric to G6PD in Xq28. <i>Genomics</i> , 1993, 17, 496-498.	2.9	36

#	ARTICLE	IF	CITATIONS
199	An archipelago of CpG islands in Xq28: identification and fine mapping of 20 new CpG islands of the human X chromosome. <i>Human Molecular Genetics</i> , 1992, 1, 275-280.	2.9	26
200	The iduronate sulfatase gene: Isolation of a 1.2-Mb YAC contig spanning the entire gene and identification of heterogeneous deletions in patients with Hunter syndrome. <i>Genomics</i> , 1992, 12, 52-57.	2.9	43
201	Yeast artificial chromosome-based genome mapping: Some lessons from Xq24â€“q28. <i>Genomics</i> , 1991, 11, 783-793.	2.9	71
202	Stable integration and expression in mouse cells of yeast artificial chromosomes harboring human genes.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 2179-2183.	7.1	34
203	Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of ccnu and vinblastine. <i>Hematological Oncology</i> , 1990, 8, 179-183.	1.7	7
204	CAVBP/DEP alternating chemotherapy for the treatment of intermediate and high grade non Hodgkin's lymphoma: Final results of a pilot study. <i>Hematological Oncology</i> , 1990, 8, 313-322.	1.7	0
205	Human glucose-6-phosphate dehydrogenase gene carried on a yeast artificial chromosome encodes active enzyme in monkey cells. <i>Genomics</i> , 1990, 7, 531-534.	2.9	38
206	Physical and genetic mapping of polymorphic loci in Xq28 (DXS15, DXS52, and DXS134): analysis of a cosmid clone and a yeast artificial chromosome. <i>American Journal of Human Genetics</i> , 1990, 46, 720-8.	6.2	22
207	Targeted Therapies in Melanoma: Successes and Pitfalls. , 0, , .		1
208	Epidemiology and Genetic Susceptibility of Breast and Ovarian Cancer in Sardinian Population. , 0, , .		0